CASE STUDY

Capturing Longitudinal Real-World Data for a Multiple Myeloma Patient Registry with Clinion EDC

Overview

A pharmaceutical sponsor needed real-world data on how independent, community-based oncology practices were treating multiple myeloma patients on a specific therapy outside a tightly controlled interventional trial setting, posing a different kind of data management challenge than a traditional clinical trial. The registry combined historical patient information with ongoing real-world follow-up, requiring investigators to capture both retrospective and prospective data within the same study while accommodating the variability of everyday clinical practice.

Conducted across seven independent community oncology sites, the registry enrolled 248 patients, each requiring detailed abstraction of prior treatment history, treatment response, and duration of response from medical records at enrollment. Patients were then followed for up to 24 months to capture treatment modifications, clinical outcomes, healthcare resource utilization, and patient-reported outcomes as they occurred in routine care. Managing these two distinct data collection approaches within a single study demanded a flexible yet structured EDC solution.

Clinion EDC helped organize the registry into two connected but purpose-built workflows: baseline intake for historical treatment data and longitudinal follow-up for ongoing real-world outcomes. Registry-specific eCRFs kept both data streams within one patient record, while study-specific edit checks helped flag missing, incomplete, or inconsistent entries across intake and follow-up forms. Centralized review gave the sponsor one place to monitor sites and whether patient records were complete, pending, or still requiring follow-up review.

Study Snapshot

Client & Industry

Pharmaceuticals

Industry

Pharmaceutical sponsor

Client

Study Design

Observational (Patient Registry)

Study Type

Oncology

Therapeutic Area

N/A (observational patient registry)

Study Phase

Not applicable

Randomization

Prospective real-world registry designed to track treatment patterns, patient-reported response, healthcare utilization, and outcomes over long-term follow-up

Study Design

Scale & Geography

United States (multi-state)

Region

7 sites

Site Count

Regulatory & Delivery

US regulatory context, per project input

Submission

Clinion EDC

Products Provided

Approximately 29 months (As per registry record and project input)

Study Duration

Challenges

Turning Routine-Care Oncology Data into an Evidence-Ready Registry Dataset

The sponsor needed to understand how patients were being treated across independent oncology practices, where data came from two different sources: historical chart abstraction at enrollment and rolling real-world follow-up over time. Across 248 patients and 25 CRF page types, the registry generated thousands of expected CRF page records that had to remain usable for review, reporting, and real-world evidence generation.

Converting Chart History into Structured Baseline Data

At enrollment, sites had to pull prior treatment history, response details, and response duration from existing medical records. The challenge was turning chart-based information into structured registry fields without leaving baseline records incomplete or inconsistent across sites.

Maintaining Follow-Up Continuity Without Fixed Trial Visits

After enrollment, sites had to capture treatment changes, resource use, patient-reported response, and outcomes for up to 24 months. Because this was a real-world registry, follow-up data did not follow the same fixed visit rhythm as an interventional trial. The challenge was keeping longitudinal patient records complete even when updates came at different times across practices.

Finding Patterns in Missing or Inconsistent Registry Data

With thousands of registry records across seven sites, the sponsor needed more than page-by-page review. The challenge was separating isolated missing fields from recurring data gaps across patients, sites, and follow-up records before the dataset could become evidence-ready.

Solutions

Turning Longitudinal Registry Data into Review-Ready Evidence with Clinion EDC

Clinion EDC was configured to support the full registry workflow: structured intake, rolling follow-up, discrepancy review, bulk query action, and registry reporting. This helped the sponsor move from passive data collection to active registry oversight.

Clinion EDC was used to create separate but connected eCRF structures for the registry’s two data streams: baseline chart abstraction and longitudinal real-world follow-up.

This helped the sponsor keep:

Prior treatment history and response data in structured intake records
Treatment changes and utilization updates in follow-up records
Patient-reported response connected to the same longitudinal subject profile
Baseline and follow-up data separated for entry, but connected for review

This made the registry record easier to interpret because chart history and ongoing real-world updates were not forced into the same rigid workflow.

With each CRF page holding multiple individual fields, the registry's dataset multiplied well beyond its page count into a very large number of individual data points to review. Clinion EDC used 350 study-specific edit checks to help control this volume by validating key registry fields during data capture and review.

This helped data managers identify edit-check triggers related to:

Missing prior treatment history fields
Incomplete treatment response or response-duration data
Follow-up records without updated treatment status
Patient-reported response fields left incomplete
Healthcare utilization or outcome fields needing correction

This made registry review more manageable because missing or inconsistent entries could be surfaced earlier, instead of accumulating across thousands of data points and becoming a larger closeout-stage problem.

When the same gap appeared across multiple patients or sites, Clinion EDC’s bulk query management capability helped data managers act on recurring issues from one workflow instead of handling each as a separate manual follow-up. Reporting views helped the sponsor monitor completion, follow-up status, and outcome-readiness across the seven-site registry.

This helped the team:

Raise related queries across affected patient records
Track response and correction status across sites
Review site-level completion and follow-up status
Identify which records were ready for final review
Prioritize records that still needed site action before closeout

This helped the sponsor keep registry review focused on evidence readiness, not just data collection.

Clinion EDC dashboards and reporting views gave the sponsor a clearer way to monitor registry completeness across the seven-site network. Instead of depending only on exported listings or manual trackers, the sponsor could visually follow data completion, follow-up progress, and review readiness.

This helped the sponsor track:

Site-wise data completion status
Patient records with pending follow-up updates
Open and resolved query status
Records ready for final review
Records still needing site action before closeout

This gave the sponsor better visibility into where the registry stood and helped prioritize the records and sites that needed attention before final review.

Outcomes

Core Results

Clinion EDC helped the sponsor manage the registry with stronger consistency, centralized visibility, and better control over longitudinal data.

Evidence-Ready Registry Data

Separate intake and follow-up eCRFs helped structure chart history, treatment updates, patient-reported responses, utilization, and outcome data within each patient record.

Scalable Gap Resolution

Edit checks and bulk query management helped data managers identify recurring gaps and manage corrections across patients and sites.

Clearer Registry Oversight

Completion and follow-up visibility helped the sponsor understand which records were review-ready and which still needed site action.

Unlock the Future of Clinical Trials with Clinion.

Cut your trial costs by 35% and accelerate your time-to-market by 30%